These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 18571929)

  • 1. Discovery of aminoquinolines as a new class of potent inhibitors of heat shock protein 90 (Hsp90): Synthesis, biology, and molecular modeling.
    Ganesh T; Min J; Thepchatri P; Du Y; Li L; Lewis I; Wilson L; Fu H; Chiosis G; Dingledine R; Liotta D; Snyder JP; Sun A
    Bioorg Med Chem; 2008 Jul; 16(14):6903-10. PubMed ID: 18571929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and optimization of novel 6-acylamino-2-aminoquinolines as potent Hsp90 C-terminal inhibitors.
    Jiang F; Guo AP; Xu JC; Wang HJ; Mo XF; You QD; Xu XL
    Eur J Med Chem; 2017 Dec; 141():1-14. PubMed ID: 29028527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragment-based hit discovery and structure-based optimization of aminotriazoloquinazolines as novel Hsp90 inhibitors.
    Casale E; Amboldi N; Brasca MG; Caronni D; Colombo N; Dalvit C; Felder ER; Fogliatto G; Galvani A; Isacchi A; Polucci P; Riceputi L; Sola F; Visco C; Zuccotto F; Casuscelli F
    Bioorg Med Chem; 2014 Aug; 22(15):4135-50. PubMed ID: 24980703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug Design, Synthesis and In Vitro Evaluation of Substituted Benzofurans as Hsp90 Inhibitors.
    Kadasi S; Costa TEMM; Arukala N; Toshakani M; Duggineti C; Thota S; Dutta Gupta S; Raj S; Penido C; Henriques MG; Raghavendra NM
    Med Chem; 2018; 14(1):44-52. PubMed ID: 28641528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp90 inhibitors and drugs from fragment and virtual screening.
    Roughley S; Wright L; Brough P; Massey A; Hubbard RE
    Top Curr Chem; 2012; 317():61-82. PubMed ID: 21647838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tricyclic series of heat shock protein 90 (Hsp90) inhibitors part I: discovery of tricyclic imidazo[4,5-c]pyridines as potent inhibitors of the Hsp90 molecular chaperone.
    Vallée F; Carrez C; Pilorge F; Dupuy A; Parent A; Bertin L; Thompson F; Ferrari P; Fassy F; Lamberton A; Thomas A; Arrebola R; Guerif S; Rohaut A; Certal V; Ruxer JM; Gouyon T; Delorme C; Jouanen A; Dumas J; Grépin C; Combeau C; Goulaouic H; Dereu N; Mikol V; Mailliet P; Minoux H
    J Med Chem; 2011 Oct; 54(20):7206-19. PubMed ID: 21972823
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification and optimization of novel Hsp90 inhibitors with tetrahydropyrido[4,3-d]pyrimidines core through shape-based screening.
    Sun HP; Jia JM; Jiang F; Xu XL; Liu F; Guo XK; Cherfaoui B; Huang HZ; Pan Y; You QD
    Eur J Med Chem; 2014 May; 79():399-412. PubMed ID: 24763261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of 8-arylsulfanyl, 8-arylsulfoxyl, and 8-arylsulfonyl adenine derivatives as inhibitors of the heat shock protein 90.
    Llauger L; He H; Kim J; Aguirre J; Rosen N; Peters U; Davies P; Chiosis G
    J Med Chem; 2005 Apr; 48(8):2892-905. PubMed ID: 15828828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hsp90 molecular chaperone inhibitors: are we there yet?
    Neckers L; Workman P
    Clin Cancer Res; 2012 Jan; 18(1):64-76. PubMed ID: 22215907
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rationally designed high-affinity 2-amino-6-halopurine heat shock protein 90 inhibitors that exhibit potent antitumor activity.
    Kasibhatla SR; Hong K; Biamonte MA; Busch DJ; Karjian PL; Sensintaffar JL; Kamal A; Lough RE; Brekken J; Lundgren K; Grecko R; Timony GA; Ran Y; Mansfield R; Fritz LC; Ulm E; Burrows FJ; Boehm MF
    J Med Chem; 2007 Jun; 50(12):2767-78. PubMed ID: 17488003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amide-tethered quinoline-resorcinol conjugates as a new class of HSP90 inhibitors suppressing the growth of prostate cancer cells.
    Nepali K; Lin MH; Chao MW; Peng SJ; Hsu KC; Eight Lin T; Chen MC; Lai MJ; Pan SL; Liou JP
    Bioorg Chem; 2019 Oct; 91():103119. PubMed ID: 31349117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improvement of inhibitor identification for heat shock protein 90α by utilizing a red-shifted fluorescence polarization probe.
    Qian J; Holskin BP; Theroff J; Underiner T; Meyer SL; Angeles TS
    Assay Drug Dev Technol; 2012 Aug; 10(4):375-81. PubMed ID: 22428803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenomics in cancer drug discovery and development: inhibitors of the Hsp90 molecular chaperone.
    Workman P
    Cancer Detect Prev; 2002; 26(6):405-10. PubMed ID: 12507224
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A fluorescence polarization assay for inhibitors of Hsp90.
    Howes R; Barril X; Dymock BW; Grant K; Northfield CJ; Robertson AG; Surgenor A; Wayne J; Wright L; James K; Matthews T; Cheung KM; McDonald E; Workman P; Drysdale MJ
    Anal Biochem; 2006 Mar; 350(2):202-13. PubMed ID: 16460658
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery and development of pyrazole-scaffold Hsp90 inhibitors.
    McDonald E; Jones K; Brough PA; Drysdale MJ; Workman P
    Curr Top Med Chem; 2006; 6(11):1193-203. PubMed ID: 16842156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Solid-phase immunoassays in mechanism-based drug discovery: their application in the development of inhibitors of the molecular chaperone heat-shock protein 90.
    Hardcastle A; Boxall K; Richards J; Tomlin P; Sharp S; Clarke P; Workman P; Aherne W
    Assay Drug Dev Technol; 2005 Jun; 3(3):273-85. PubMed ID: 15971989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of N-pyridoyl-Δ
    Kadasi S; Yerroju R; Gaddam S; Pullanagiri N; Chary M; Pingili D; Raj S; Raghavendra NM
    Arch Pharm (Weinheim); 2020 Feb; 353(2):e1900192. PubMed ID: 31808979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New heat shock protein (Hsp90) inhibitors, designed by pharmacophore modeling and virtual screening: synthesis, biological evaluation and molecular dynamics studies.
    Abbasi M; Amanlou M; Aghaei M; Bakherad M; Doosti R; Sadeghi-Aliabadi H
    J Biomol Struct Dyn; 2020 Aug; 38(12):3462-3473. PubMed ID: 31452440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a high-throughput screening cancer cell-based luciferase refolding assay for identifying Hsp90 inhibitors.
    Sadikot T; Swink M; Eskew JD; Brown D; Zhao H; Kusuma BR; Rajewski RA; Blagg BS; Matts RL; Holzbeierlein JM; Vielhauer GA
    Assay Drug Dev Technol; 2013 Oct; 11(8):478-88. PubMed ID: 24127661
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in the Discovery of Novel HSP90 Inhibitors: An Update from 2014.
    Xiao Y; Liu Y
    Curr Drug Targets; 2020; 21(3):302-317. PubMed ID: 31465284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.